Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBIT: 2010-2025

Historic EBIT for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$20.9 million.

  • Altimmune's EBIT rose 15.78% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 19.18%. This contributed to the annual value of -$103.2 million for FY2024, which is 7.55% down from last year.
  • Altimmune's EBIT amounted to -$20.9 million in Q3 2025, which was up 9.00% from -$22.9 million recorded in Q2 2025.
  • Altimmune's 5-year EBIT high stood at -$14.9 million for Q1 2021, and its period low was -$33.6 million during Q4 2023.
  • Its 3-year average for EBIT is -$24.1 million, with a median of -$22.9 million in 2025.
  • Per our database at Business Quant, Altimmune's EBIT tumbled by 123.12% in 2021 and then rose by 26.04% in 2024.
  • Over the past 5 years, Altimmune's EBIT (Quarterly) stood at -$24.0 million in 2021, then grew by 3.71% to -$23.1 million in 2022, then crashed by 45.59% to -$33.6 million in 2023, then increased by 26.04% to -$24.9 million in 2024, then increased by 15.78% to -$20.9 million in 2025.
  • Its last three reported values are -$20.9 million in Q3 2025, -$22.9 million for Q2 2025, and -$21.8 million during Q1 2025.